Abstract
Atopic dermatitis (AD) and psoriasis are common, chronic inflammatory skin diseases that carry a significant comorbidity burden, with patient populations showing increased prevalence of a range of conditions, including cardio-metabolic, respiratory, and psychiatric disorders. Predictive biomarkers for comorbidity development can help direct at-risk patients towards preventative lifestyle and/or clinical interventions which will improve patient outcomes and reduce overall healthcare burden. We identified 92 established or hypothesised AD and psoriasis comorbidities (73 common to both diseases) with prevalence >2% in UK Biobank (UKB).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
